← Latest news 
Sun Pharma buys Organon to boost oncology dermatology and women health fast
Business
Published on 27 April 2026
A New Jersey deal could open China and Brazil next
Sun Pharma is strengthening its global footprint with the acquisition of New Jersey based Organon. The deal expands its portfolio across dermatology, oncology, and women’s health while creating a route into markets such as China and Brazil. With strong finances underpinning the move, Sun expects quicker returns as it scales the combined capabilities and reach.
- Sun Pharma acquires Organon to deepen core therapy focus
- The portfolio gain spans dermatology, oncology, and women’s health
- The acquisition may accelerate entry into China and Brazil
- Financial strength is positioned to support quicker returns
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times